Celltrion applies for approval in US for eye treatment biosimilar

The biopharmaceutical company now covers ophthalmology as well as autoimmune disease and cancer medicine

Celltrion applies for approval in US for eye treatment biosimilar
Jeong Min Nam 1
2023-06-30 14:34:31 peux@hankyung.com
Bio & Pharma

South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P42, a biosimilar of the eye treatment Eylea.

Based on the results of Phase 3 clinical trials worldwide of CT-P42, Celltrion applied with the FDA for approval of Eylea for all indications (excluding pediatric) like wet macular degeneration and diabetic macular edema (DME). After the US, the company will sequentially seek the green light in major economies such as those in Europe.

Celltrion confirmed CT-P42's equivalence to and similarity with Eylea in Phase 3 trials on 348 DME patients in 13 countries like the Czech Republic, Hungary, Poland and Spain.

Developed by Regeneron of the US, Eylea is a blockbuster drug with global sales last year of $9.7 billion. Its exclusive rights in the US expire in May next year and its patents in Europe in November 2025.

“We will do our best to expand our biosimilar portfolio to ophthalmology by sequentially applying for approval in major countries like those in Europe starting with the US,” a Celltrion source said.

The company will complete this year's applications for global approval for up to five biosimilars including CT-P42.

Write to Jeong Min Nam at peux@hankyung.com
#Celltrion #eye treatment biosimilar #Eylea #CT-P42 #US #FDA #biosimilar portfolio

Celltrion puts Takeda’s assets up for sale after 3 years

Celltrion puts Takeda’s assets up for sale after 3 years

Celltrion's headquarters in Incheon, South Korea (Courtesy of Yonhap) South Korea’s Celltrion Inc. has put its Japanese Takeda Pharmaceutical Co.'s primary care assets acquired in 2020 on sale as the biosimilar giant is raising money to transform into a drug developer and considering inve

Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US

Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US

South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA) for the phase 3 investigational new drug (IND) application of its biosimilar CT-P53 for Ocrevus (ingredient: ocrelizumab), a treatment for multi

Celltrion to expand biosimilar portfolio to 11 by 2025

Celltrion to expand biosimilar portfolio to 11 by 2025

South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it plans to beef up its portfolio by applying for regulatory approval for five additional biosimilars by the end of the year. Celltrion aims to bring its total biosimilar offering to more than ten by 2025, a sign

Celltrion to develop Humira biosimilar oral medication with US firm

Celltrion to develop Humira biosimilar oral medication with US firm

South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics for the development of an oral formulation of adalimumab (CT-P17).Following their collaboration agreement for the development of an oral formulati

Celltrion’s Remsima SC praised in Europe as preferred biosimilar

Celltrion’s Remsima SC praised in Europe as preferred biosimilar

A rheumatologist speaks at a European Congress of Rheumatology symposium hosted by Celltrion under the theme “Infliximab IV to SC - Mainstay Therapy in Rheumatology” on June 2, 2023 MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosi
(* comment hide *}